PRTG vs. ENSC, GNPX, LGVN, SSY, THAR, DRUG, ARTL, STSS, AFIB, and VERO
Should you be buying Portage Biotech stock or one of its competitors? The main competitors of Portage Biotech include Ensysce Biosciences (ENSC), Genprex (GNPX), Longeveron (LGVN), SunLink Health Systems (SSY), Tharimmune (THAR), Bright Minds Biosciences (DRUG), Artelo Biosciences (ARTL), Sharps Technology (STSS), Acutus Medical (AFIB), and Venus Concept (VERO). These companies are all part of the "medical" sector.
Portage Biotech (NASDAQ:PRTG) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
Portage Biotech has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.
Portage Biotech has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -476.29%. Portage Biotech's return on equity of -177.66% beat Ensysce Biosciences' return on equity.
Portage Biotech currently has a consensus target price of $8.50, suggesting a potential upside of 2,841.18%. Ensysce Biosciences has a consensus target price of $7.00, suggesting a potential upside of 1,144.89%. Given Portage Biotech's higher probable upside, research analysts plainly believe Portage Biotech is more favorable than Ensysce Biosciences.
Ensysce Biosciences has higher revenue and earnings than Portage Biotech. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.
13.4% of Portage Biotech shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 39.4% of Ensysce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Portage Biotech's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.
Portage Biotech received 10 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. However, 60.00% of users gave Ensysce Biosciences an outperform vote while only 59.09% of users gave Portage Biotech an outperform vote.
Summary
Portage Biotech beats Ensysce Biosciences on 8 of the 14 factors compared between the two stocks.
Get Portage Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Portage Biotech Competitors List
Related Companies and Tools
